Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564527 | 0.72 | AGTR2 (0.40) | AGTR2CTSLCTSBCTSKPTPN1 | |
| SCHEMBL3064134 | 0.72 | AGTR2 (0.43) | AGTR2CTSLCTSBCTSKBUB1 | |
| SCHEMBL564528 | 0.72 | AGTR2 (0.41) | AGTR2CTSLCTSBCTSKBUB1 | |
| SCHEMBL562781 | 0.71 | AGTR2 (0.43) | AGTR2CTSLCTSBCTSKBUB1 | |
| SCHEMBL12206451 | 0.71 | AGTR2 (0.43) | AGTR2CTSLCTSBCTSKBUB1 | |
| SCHEMBL21753086 | 0.69 | NAMPT (0.52) | AGTR2CTSLCTSBCTSKNAAA | |
| SCHEMBL10239722 | 0.68 | AGTR2 (0.40) | AGTR2CTSLCTSBCTSKBUB1 | |
| SCHEMBL29076932 | 0.68 | L3MBTL1 (0.53) | CTSLCTSBCTSKHPGD | |
| SCHEMBL29076936 | 0.68 | L3MBTL1 (0.53) | CTSLCTSBCTSKHPGD | |
| SCHEMBL28778767 | 0.68 | KMT2A (0.52) | AGTR2CTSLCTSBCTSKBUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492416-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB Biopharma SRL (BE) | 2012-02-09 | — | — | US | disclosed |
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | DIFFERDING EDMOND (BE) | 2005-08-04 | — | — | US | disclosed |
| US-6911461-B2 | For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse | UCB, S.A. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-20040116507-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | AGTR2 2408/4885CTSL 2002/4885CTSB 1036/4885 |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | CYP1B1, OGDH, CYP1A2 | AGTR2 2408/4885CTSL 2002/4885CTSB 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.